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In the last 15 years, sentinel lymph node biopsy has
dramatically altered the practice of surgical oncology.
Patients with small primary tumors of the breast or
skinwhohavenegative regional lymphnodes no longer
suﬀer the consequences of regional lymphadenectomy,
in particular lymphedema. The adoption of sentinel
lymph node biopsy in patients with breast cancer and
melanomawas basedmainly on large single-institution
series led by respected leaders in their ﬁelds. Since then,
largermulti-institutional trials have been reported that
complement the single-institutional series.1 Sentinel
lymph node status is part of the American Joint
Committee on Cancer staging system for breast can-
cer2 and cutaneous melanoma.3
The last 15 years have witnessed numerous studies
of the sentinel lymph node biopsy technique in pa-
tients with gynecological cancers, including endome-
trial, vulvar, and cervical cancers. Despite this
activity, sentinel lymph node biopsy has not replaced
lymphadenectomy as the standard for surgical man-
agement of patients with such cancers.
Endometrial cancer is the most common gyneco-
logical cancer in the United States. Lymphatic
drainage of the endometrium is complicated; because
the uterus is a midline structure, this drainage is
presumed to be bilateral. The lower uterine segment
drains, as does the cervix, to the pelvic lymph nodes,
whereas the uterine fundus drains along the gonadal
vessels to para-aortic sites up to the left renal vein.
These drainage patterns necessitate extensive pelvic
and para-aortic lymphadenectomy to stage the pa-
tients disease. Lymphedema does not appear to be a
common complication of these operations, although
it has not been well studied. Several intraoperative
lymphatic mapping techniques have been reported
for endometrial cancer, including the use of cervical,
fundal,4 and hysteroscopic injections,5 the latter of
which is the most promising in terms of sentinel
lymph node identiﬁcation. However, this technique
can be quite cumbersome and has not progressed
much beyond the feasibility-testing stage.
Vulvar cancer was the ﬁrst and most promising
gynecological site for the sentinel lymph node biopsy
strategy. Because it involves a cutaneous tumor, pe-
ritumoral injections are easy; another factor making
the vulva an ideal site for sentinel lymph node biopsy
is that the sentinel lymph node is always located in
the groin. Lower-extremity lymphedema is common,
especially when postoperative radiotherapy is given
to lymph node-positive patients. Because vulvar
cancer is rare—only 4,000 cases are diagnosed each
year in the United States—accrual to clinical trials of
sentinel lymph node biopsy for vulvar cancers has
been slow. A large validation trial conducted by the
Gynecologic Oncology Group and including over 400
patients is awaiting completion. A large observa-
tional trial in the Netherlands is awaiting maturation
of results and publication.6 The current treatment
guidelines for vulvar cancer call for regional radio-
therapy to patients with positive lymph nodes. For
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this reason, gynecology oncologists (and patients)
will be willing to accept sentinel lymph node biopsy
alone, only if it is associated with a very low false-
negative rate.
Cervical cancer, the most common gynecological
cancer in the world, is a sexually transmitted disease
resulting from infection with certain subtypes of hu-
man papillomavirus. The infection is associated with
a premalignant phase that is protracted and detect-
able using an inexpensive screening test—the Pap
smear. The incidence of this cancer continues to de-
cline in populations with good pap smear screening
programs (fewer than 10,000 cases are diagnosed per
year in the United States), although it is still rising in
unscreened populations.
The cervix is an excellent target for the sentinel
lymph node mapping strategy. The cervix is a midline
structure with complex lymphatic drainage to multi-
ple pelvic, common iliac, and low para-aortic sites.
Cervical tumors are visible to the naked eye and easy
to inject, and all the potential drainage sites can be
accessed through a single incision. In addition, sen-
tinel lymph node biopsy for cervical cancer can be
performed laparoscopically, an especially attractive
feature as increasing numbers of radical hysterecto-
mies are being performed using this technique. Sen-
tinel lymph node biopsy is also a good complement to
fertility-sparing procedures such as radical trache-
lectomy. However, the usefulness of such a biopsy in
patients with cervical cancer has been questioned,
since lower-extremity lymphedema in such patients
undergoing standard lymph node dissection appears
to be less common and less severe than in those
undergoing groin dissection. In addition, parametrial
lymph nodes that are immediately adjacent to the
cervix cannot be imaged with lymphoscintigraphy
and are diﬃcult to observe in the operating room.
Coutant et al. 7 reported on experience with sentinel
lymphnode biopsy inpatientswith cervical cancer. This
series included a heterogeneous group of patients with
tumors ranging in size from microscopic to 7 cm and
patients who are usually excluded from radical-hyster-
ectomy sentinel lymph node biopsy series, such as those
with stage-Ib2, -IIa, and -IIB disease. Some of these
patients received neoadjuvant chemotherapy before
surgical treatment of the cervix and 15% underwent
lymphadenectomy only, without surgical treatment to
remove the cervix after the sentinel lymph node biopsy
(presumably because they had locally advanced disease
or gross nodal involvement). There were 11 lymph
node-positive patients in the series, and 2 (18%) were
reported as having false-negative ﬁndings on sentinel
lymph node biopsy, both of whom had stage-IIb dis-
ease. The false-negative rate in the stage-I patients was
zero. These ﬁndings conﬁrm clinical observations from
multiple disease sites that sentinel lymph node biopsy is
best performed in patients with small localized tumors
and grossly uninvolved lymph nodes.
The results of the series reported by Barranger also
conﬁrm another common observation regarding
sentinel lymph node biopsy for cervical cancer. De-
spite the midline position of the cervix, only a little
more than half of all patients with cervical cancer
were found to have bilateral sentinel lymph nodes
(only 45% in the current series). It is not known what
eﬀect the exact injection site, obstetrical trauma,
endometriosis, or pelvic inﬂammatory disease might
have on lymphatic drainage.
Hauspey et al.8 have recently reported their single-
institution series of over 40 patients with stage-I
cervical cancer and reviewed over 800 published
cases. This group suggested that the false-negative
rate for sentinel lymph node biopsy in these patients
has been overstated in the literature and suggest two
simple guidelines to protect against false-negative
results. First, when a sentinel lymph node is identiﬁed
on one side of the pelvis only, a lymphadenectomy
should always be performed on that side. Second, the
parametrium should always be removed with the
cervix so that any parametrial sentinel lymph nodes
are removed with the specimen. These guidelines will
improve the safety of the sentinel lymph node biopsy
procedure in these patients. However, the total
number of node-positive cervical cancer patients re-
ported in the literature is still under 200, a very small
number on which to base change in standard practice.
In addition, many innovative management ap-
proaches are being investigated—such as a two-step
laparoscopic sentinel lymph node biopsy and a simple
vaginal trachelectomy strategy described by Rob and
colleagues9—and these need development. For cer-
vical cancer, as in vulvar cancer, current treatment
guidelines are heavily dependent on lymph node
status; therefore, a low false-negative rate is necessary
to avoid relapses in otherwise curable patients.
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